Clinical Trial Update: Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents (MK-8237-008) [Phase 1]

View source ↗

Summary

Phase 1 safety study of MK-8237 in adolescents with house-dust-mite allergic rhinitis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis

Drugs mentioned

• MK-8237

Snippet

Sponsor: ALK-Abelló A/S | Conditions: Rhinitis, Allergic, Perennial, Rhinitis, Allergic, Nonseasonal | Phase 1 | Status: COMPLETED | Results posted: 2017-02-13